Physician profile
Amy Golaszewski
NPI 1689393217
$5,641.10
in general payments reported to CMS, 2019-2025
27 companies · $2,781 in 2025
The $2,781 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $32.42 · 2023: $1,209 · 2024: $1,619 · 2025: $2,781.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,461 · Education: $148.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,460.70 |
| Education | $147.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $869.86 | 2023-2025 | |
| Abbvie INC. | $811.76 | 2023-2025 | |
| Sun Pharmaceutical Industries INC. | $611.69 | 2023-2025 | Winlevi, Ilumya |
| Arcutis Biotherapeutics, INC. | $411.60 | 2024-2025 | Zoryve |
| Pfizer INC. | $287.31 | 2023-2025 | |
| Janssen Biotech, INC. | $280.23 | 2023-2025 | Tremfya, Simponi, Simponi Aria |
| Galderma Laboratories, L.P. | $275.63 | 2023-2025 | Nemluvio, Oracea, Epsolay |
| Lilly USA, LLC | $269.06 | 2023-2025 | Olumiant, Ebglyss, Taltz |
| Genzyme Corporation | $267.30 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $243.81 | 2023-2025 | Dupixent, Libtayo |
| Amgen INC. | $214.89 | 2023-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $170.51 | 2025 | |
| Ucb, INC. | $124.38 | 2024-2025 | Bimzelx |
| Organon LLC | $117.09 | 2025 | Vtama |
| E.R. Squibb & Sons, L.L.C. | $113.04 | 2024 | Sotyktu |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $112.38 | 2023-2025 | Opzelura |
| Dermavant Sciences, INC. | $96.09 | 2023-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $83.11 | 2023-2024 | Spevigo |
| Verrica Pharmaceuticals INC. | $45.30 | 2023-2024 | Ycanth |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $44.99 | 2025 | Jublia, Siliq, Cabtreo |
| Biofrontera INC. | $41.91 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Epi Health, LLC | $32.42 | 2022 | |
| Blueprint Medicines Corporation | $28.37 | 2025 | Ayvakit |
| Lnhc, INC | $24.97 | 2025 | Zelsuvmi |
| Sandoz INC. | $24.71 | 2023 | Hyrimoz |
| Kyowa Kirin, INC. | $22.71 | 2024 | Poteligeo |
| Journey Medical Corporation | $15.98 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Golaszewski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.